Ganoderma Lucidum Spore Oil Softgel (Reishi mushroom spore oil softgel) uses organic shell-broken Ganoderma
spore powder as ingredients, combined with our patented supercritical CO2 extraction
technology, making it the ultimate Ganoderma dietary supplement product on the
market with the highest purity.
When it comes to
dietary supplement product, safety is always the top priority. Our Ganoderma
ingredient comes from our self-built Ganoderma farm, which has acquired 4
organic certifications from China, Japan, the US, and the EU. We make sure
every step of the whole process is safe
and traceable without any kind of contamination.
The supercritical
CO2 extraction technology uses liquefied CO2 as a solvent to dissolve spore oil from shell-broken
spore powder under hyperbaric environment. After CO2 evaporates, it
is left with pure Reishi Spore Oil. This
method makes sure that no chemical reagent will be left in the spore oil during
the extraction process while still maintaining the highest purity. The
triterpenes content in this product is as high as over 20%.
Ganoderma spore
oil is great for people with severe chemical liver damage due to long-term drinking
and high pressure. It also assists cancer treatment and helps reduce the side
effects from chemo and radiotherapy and
greatly increase the level of immune cells. Reports have shown that Ganoderma Oil can inhibit the growth of internal and external tumor, with a success
rate of 56.3%.
Recommended
dosage: 2 times a day, 2 capsules each time.
Ganoderma Lucidum Spore Oil Softgel,Reishi Spore Oil,Ganoderma Oil Ganoherb International Inc. , http://www.ganoherb.us
Guangdong's second batch of drug price review and declaration in 2010
All related pharmaceutical production and operation enterprises:
Â
In order to further standardize drug price behaviors and strengthen drug price regulation, it is based on the "Notice of the National Development and Reform Commission's General Office on Further Strengthening the Management of Drug Price" (No. 195 of DSC [2010]) and the General Office of the National Development and Reform Commission on Strengthening Drugs. In the spirit of the Supplementary Notice on Related Issues such as Price Management (Shangfa Power [2010] No. 214), the relevant matters of the second batch of drug price review and drug price application are hereby notified as follows:
Â
First, review the scope, content and time. The scope of the variety of the country has not yet announced the price or the implementation of the trial price, as well as other drugs need to review (see attachment), review the contents including production costs, factory (port) prices, supply price, bid Price, actual retail price, etc. The company should submit a written application to the Bureau after filing in the “General Price Filing System†of the Guangdong Price Information Network (http://) “Guangdong Pharmaceutical Price Supervision Service Platformâ€. The deadline for submission of application materials is September 30, 2010. For drugs that are not declared on time, the Bureau will use the specifications of the varieties and formulations of the bid invitation , refer to the national minimum bid price and the factory (port) price of the same formulation drug. The price is determined on the principle of low.
Â
Second, the application materials requirements. The second batch of reviews of drug prices and daily drug price adjustment applications need to fill in the form, the submission of written materials and approval procedures and other matters, in accordance with the "on the first batch of drugs price review review" (Guangdong Price Letter (2010) No. 550) provides for implementation.
Â
All new listings, new dosage forms, and price increase categories (including the special investigation of the Guangdong Province No. [2010] No. 550 document) shall be submitted to the provincial-level price authority or accounting firm (no relevant government agencies in the past three years). , trade associations and other penalties, punishment) review the audit of the cost and price of the audit report. If the information provided by the company needs to be kept confidential, it should be noted. Forms and copies of materials provided with official seals do not need to check the original purchase invoices.
Â
The price of drugs that have been reported on the “Guangdong Provincial Drug Price Management Service Platform†and have not been reviewed and approved, because the current reporting price is different from the previous one, the applicant should apply again according to the provisions of this notice.
Â
Enterprises should truthfully fill in the relevant materials, falsify frauds, and report false prices and costs. The Bureau will impose penalties in accordance with relevant regulations and expose them.
Â
Third, material examination and acceptance. After the enterprise declares and receives the application number on line, please submit the written material signed by the corporate legal representative and affixed with the official seal to the price service acceptance hall of our bureau according to the time of the appointment, and at the same time, in the top right corner of the cover page of the material. The acceptance number is marked. After the audit is consistent with the online submission of the information, the acceptance of the receipt of the material in accordance with the provisions shall be regarded as formally accepted. It is difficult for the enterprise to provide the original invoice (including the rechecked version of the Guangdong letter [2010] No. 550) and shall submit the The notary office confirms the original copy of the notarial certificate that corresponds to the original copy.
Â
Fourth, the examination and approval result inquiry. For the drug price declared by the company, the Bureau will focus on the review and publication. The specific price plan publicity and acceptance examination and approval will be on the homepage of Guangdong Price Information Network, "differential pricing declaration" and "general pricing report" respectively. In the system column, the reporting company can make inquiries based on the application number in time.
Â
V. Drug price declaration. In the future, daily drug price adjustment applications will be reported through the "Guangdong Pharmaceutical Price Supervision Service Platform."
Â
Differentiated pricing drugs (marking the price of the manufacturer's name, including the country's and the province's announced separate pricing, premium price and differential pricing supplementary specifications) and the price of ordinary pricing drugs, respectively, entered the "differentiation of the provincial pharmaceutical price monitoring service platform. "Declaration Declaration", "General Price Declaration" system to fill in and upload relevant materials.